Delving into the Latest Updates on Chemlmmune Therapeutics LLC with Synapse

Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma

A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed bronchial asthma (BA) and the eosinophil blood level 2 times within 1 week interval of ≥ 300 cells/μl.
Study design was developed by Chemlmmune Therapeutics LLC, Russia in cooperation with Eurrus Biotech GmbH, Austria.

开始日期2020-12-16

申办/合作机构

Chemlmmune Therapeutics LLC

[+1]

100 项与 Chemlmmune Therapeutics LLC 相关的临床结果

登录后查看更多信息

0 项与 Chemlmmune Therapeutics LLC 相关的专利（医药）

登录后查看更多信息

100 项与 Chemlmmune Therapeutics LLC 相关的药物交易

登录后查看更多信息

100 项与 Chemlmmune Therapeutics LLC 相关的转化医学

登录后查看更多信息